Amendments to the Specification

In accordance with revised 37 C.F.R. § 1.121, please amend the specification as follows, with deletions shown by strikethrough and additions shown by underlining:

Please amend the paragraph beginning on page 21, line 27 and ending on page 22, line 9 as follows:

Briefly, phosphorothioate or methylphosphonate derivatives of a sequence complimentary to regions of the *art/trs* genes of HIV having the sequence 5'-TCGTCGCTGTCTCG-3' (SEQ ID NO: 1) are prepared according to the method of Matsukura et al. Three hundred ~~300~~ milligrams (300 mg) of CRL-8131 is added to 10 ml of 0.9% $NaCl_2$ and the mixture is solubilized by storage at temperatures of 2-4°C_2 until a clear solution is formed. The desired antisense oligonucleotide subsequently is mixed with the copolymer solution to provide a concentration effective in inhibiting viral activity when administered to a patient infected with the HIV virus. Generally the effective amount of antisense compound will be such that the final concentration in the blood is in the range of 1 μM to 100 μM, although other effective amounts of antisense compounds outside this range may be found for specific antisense compounds. One skilled in the art can readily test the relative effectiveness of any particular antisense oligoncleotide according to the *in vivo* test of Matsukura et al.